Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
HeraMED Ltd. ( (AU:HMD) ) has shared an update.
HeraMED Limited has reported a 10.3% decline in revenues from ordinary activities to $431,605 for the year ended 31 December 2025, while its net loss after tax narrowed by 24.8% to $4.13 million compared with the prior year. The company did not declare any dividends for the current or previous financial periods, and net tangible assets per share fell from 0.23 cents to 0.11 cents, although its audited financial statements received an unmodified opinion, indicating compliance with accounting standards and no material audit issues.
The contraction in revenue alongside a reduced loss suggests HeraMED has made some progress in cost control or restructuring, but it continues to operate at a significant loss, which may weigh on investor sentiment and its capacity to fund growth organically. The decline in net tangible assets per ordinary security highlights ongoing balance sheet pressure, potentially affecting future capital-raising dynamics and valuation, even as the clean audit opinion provides a measure of assurance on the reliability of its reported financial position.
The most recent analyst rating on (AU:HMD) stock is a Hold with a A$0.04 price target. To see the full list of analyst forecasts on HeraMED Ltd. stock, see the AU:HMD Stock Forecast page.
More about HeraMED Ltd.
HeraMED Limited is an Australian-listed company that reports under Australian Accounting Standards. While the release does not specify its industry or products, the group operates through a consolidated structure and is subject to standard local financial reporting and audit requirements.
Average Trading Volume: 742,026
Technical Sentiment Signal: Buy
Current Market Cap: A$41.21M
Find detailed analytics on HMD stock on TipRanks’ Stock Analysis page.